A biocompatible copper based therapeutic nanoplatform for CD44 specific tumor targeted therapy and potent immune reprogramming 

Yifeng Fang et al.

Biomaterials. 2026 Jun 13;335:124373. doi: 10.1016/j.biomaterials.2026.124373. Online ahead of print.

Published on June 18, 2026

Abstract

ABSTRACT

Despite advances in oncology, the dual challenge of achieving precise tumor-targeted therapy while simultaneously activating antitumor immunity remains a major clinical barrier. In this study, we engineered a biocompatible copper-based platform, hyaluronic acid (HA) modified Cu ions based therapeutic (B-Cu/HA), that integrates selective tumor targeting, intrinsic cytotoxicity, and immune activation within a single therapeutic system. Leveraging the HA-CD44 interaction, B-Cu/HA exhibited preferential accumulation and prolonged retention in CD44-overexpressing tumors, while maintaining an excellent biosafety profile. Across multiple cancer models, B-Cu/HA robustly inhibited tumor progression. Mechanistically, it induced cuproptosis through upregulation of FDX1 and aggregation of lipoylated DLAT, and triggered ROS-mediated activation of the cGAS-STING pathway, promoting immunogenic cell death. Transcriptomic analysis revealed activation of hypoxia and cytokine signaling pathways, aligning with enhanced CD8+ T-cell cytotoxicity and remodeling of the tumor immune microenvironment. The animal models studies demonstrated that B-Cu/HA significantly suppressed tumor growth without systemic toxicity, and synergistically enhanced the efficacy of the immune checkpoint inhibitors anti-TIGIT. Together, these findings establish B-Cu/HA as a multifunctional, immunomodulatory formulation that offers a clinically translatable strategy to enhance tumor immunotherapy and overcome resistance in CD44-overexpressing tumors.

PMID:42314235 | DOI:10.1016/j.biomaterials.2026.124373

 Read More

← Back to Publications
Mikkola Lea et al.Biochem Biophys Rep. 2026 Nov 9;48:102875. doi: 10.1016/j.bbrep.2026.102875. eCollection 2026 Dec.
Gautier Follain et al.Bio Protoc. 2026 Nov 5;16(21):e5861. doi: 10.21769/BioProtoc.5861. eCollection 2026 Nov 5.
Francesca Bottanelli et al.J Cell Sci. 2026 Nov 1;139(21):jcs265433. doi: 10.1242/jcs.265433. Epub 2026 Nov 12.
Aliaa E Ali et al.Hum Mutat. 2026 Nov 8;2026:8234670. doi: 10.1155/humu/8234670. eCollection 2026.
Marie Christine Goess et al.J Crohns Colitis. 2026 Nov 7;20(11):jjag182. doi: 10.1093/ecco-jcc/jjag182.